<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="tolerability of dermo-cosmetic products in preventing skin reactions associated with" exact="cancer" post="treatments. Patients and methods A 12-product kit was supplied"/>
 <result pre="used. Results A total of 147 patients were enrolled in" exact="cancer" post="services in Germany, France, Italy, Spain, and Canada. Mean"/>
 <result pre="of patients using EGFR inhibitors. 5 Other common toxicities include" exact="paronychia" post="(inflammation of the lateral nail wall), abnormal hair growth"/>
 <result pre="cases can lead to decreased compliance or even interruption of" exact="cancer" post="treatment. 14, 15 For these reasons, research into supportive"/>
 <result pre="and manage skin reactions to maintain quality of life in" exact="cancer" post="patients undergoing chemotherapy (with or without radiotherapy). Patients and"/>
 <result pre="considered. Patients were excluded if they had metastatic cancer, primary" exact="skin cancer," post="any preexisting skin disorders that could interfere with the"/>
 <result pre="that could interfere with the results of the study (like" exact="atopic dermatitis," post="contact dermatitis, psoriasis, rosacea, severe photosensitivity, scleroderma, xerosis), and"/>
 <result pre="interfere with the results of the study (like atopic dermatitis," exact="contact dermatitis," post="psoriasis, rosacea, severe photosensitivity, scleroderma, xerosis), and any known"/>
 <result pre="dermatitis, psoriasis, rosacea, severe photosensitivity, scleroderma, xerosis), and any known" exact="allergy" post="to cosmetic ingredients or past history of allergy to"/>
 <result pre="any known allergy to cosmetic ingredients or past history of" exact="allergy" post="to cosmetic products. Products Once enrolled, each patient received"/>
 <result pre="skin (skin types IV–VI). Thirty-nine percent were treated for female" exact="cancer" post="(ie, ovary or breast), 31% for digestive system cancer"/>
 <result pre="female cancer (ie, ovary or breast), 31% for digestive system" exact="cancer" post="(ie, colon or rectum), 20% for a head and"/>
 <result pre="digestive system cancer (ie, colon or rectum), 20% for a" exact="head and neck cancer," post="and 10% for other cancer types (including leukemia or"/>
 <result pre="for a head and neck cancer, and 10% for other" exact="cancer" post="types (including leukemia or pancreatic carcinoma). Sixteen percent were"/>
 <result pre="and neck cancer, and 10% for other cancer types (including" exact="leukemia" post="or pancreatic carcinoma). Sixteen percent were initiating chemotherapy alone"/>
 <result pre="erythema, 2 (6.5%) had acneiform rash, and edema, pruritus or" exact="rash" post="was reported for 1 patient each. The frequency of"/>
 <result pre="without concomitant radiotherapy). However, in a similar study, performed with" exact="breast cancer" post="patients, 85% of patients had at least 1 skin"/>
 <result pre="concomitant radiotherapy). However, in a similar study, performed with breast" exact="cancer" post="patients, 85% of patients had at least 1 skin"/>
 <result pre="also supported by the fact that during this study, radiation" exact="dermatitis" post="was a frequent skin toxicity. Therefore the use of"/>
 <result pre="(alone or associated with chemotherapy). Nevertheless, as previously demonstrated for" exact="breast cancer" post="patients receiving radiotherapy only, regular users of well-tolerated skin"/>
 <result pre="or associated with chemotherapy). Nevertheless, as previously demonstrated for breast" exact="cancer" post="patients receiving radiotherapy only, regular users of well-tolerated skin"/>
 <result pre="of supportive oncodermatology: the study of dermatologic adverse events to" exact="cancer" post="therapies J Am Acad Dermatol 2011 65 3 624"/>
 <result pre="Holmes-Rovner M Northouse LL et al. Primary care perspectives on" exact="prostate cancer" post="survivorship: implications for improving quality of care Urol Oncol"/>
 <result pre="M Northouse LL et al. Primary care perspectives on prostate" exact="cancer" post="survivorship: implications for improving quality of care Urol Oncol"/>
 <result pre="Chosidow O et al. The management of skin reactions in" exact="cancer" post="patients receiving epidermal growth factor receptor targeted therapies J"/>
 <result pre="27043866 11 Abdel-Rahman O Fouad M Correlation of cetuximab-induced skin" exact="rash" post="and outcomes of solid tumor patients treated with cetuximab:"/>
 <result pre="R Kinahan K Bennett CL Lacouture ME Dermatologic challenges in" exact="cancer" post="patients and survivors Oncology (Williston Park) 2007 21 12"/>
 <result pre="VI 4% 2% Cancer type N=79 N=63 Not relevant  Female" exact="cancer" post="(ovary, breast…) 25% 57%  Digestive system cancer (colon, rectum…)"/>
 <result pre="Not relevant  Female cancer (ovary, breast…) 25% 57%  Digestive system" exact="cancer" post="(colon, rectum…) 30% 30%  Head and neck (ENT) cancer"/>
 <result pre="system cancer (colon, rectum…) 30% 30%  Head and neck (ENT)" exact="cancer" post="28% 10%  Other cancer (leukemia, pancreas…) 17% 3% Therapeutic"/>
 <result pre="30% 30%  Head and neck (ENT) cancer 28% 10%  Other" exact="cancer" post="(leukemia, pancreas…) 17% 3% Therapeutic treatment type N=79 N=63"/>
</results>
